Loading
TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.
TST001 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Transcenta Therapeutics (Hangzhou) Co., Ltd., in metastatic cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody, as described in the registry record.
1.TST001 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TST001" OR ABSTRACT:"TST001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TST001, not a curated reading list.
Shares Transcenta and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.